Pharmaceuticals

Taiho Ventures, LLC Celebrates 10th Anniversary

TOKYO and MENLO PARK, Calif., April 15, 2026 /PRNewswire/ -- Taiho Pharmaceutical Co., Ltd. (Taiho Pharmaceutical) and Taiho Ventures, LLC (TVL), a strategic corporate venture capital (CVC) arm of Taiho Pharmaceutical, announced on April 15 that TVL has reached its 10th anniversary since its est...

2026-04-15 14:00 445

WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing

* Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients * Zero non-conformities demonstrates company's robust quality management system SHANGHAI, April 14, 2026 /PRNewswire/ -- WuXi Biologics...

2026-04-15 10:39 335

SST001, an α-syn PET tracer from Mabwell's incubated company SynuSight Biotech, received NMPA approval to initiate a clinical trial

SHANGHAI, April 15, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that18F-FD4 (R&D code: SST001), an α-synuclein (α-syn) targeted PET tracer independently developed by its incubated company SynuSight Bio...

2026-04-15 08:00 935

Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix's pivotal IPAX BrIGHT trial[1], marking the first radiopharmaceutical...

2026-04-15 06:50 947

Mexican company Farmacias Similares brings Dr. Simi to Tokyo in Japan debut

A pop-up store is being opened by Farmacias Similares in Shibuya, which is in the heart of Tokyo. TOKYO, April 15, 2026 /PRNewswire/ -- Dressed as a samurai and with his trademark energetic attitude, Dr. Simi—the face of Farmacias Similares— greets curious visitors stopping by the company's pop-...

2026-04-15 06:00 1063

Advances in Parkinson's Disease Cell Therapy: XellSmart Launches a Multicenter Phase II Clinical Trial Following Encouraging Phase I Results

SUZHOU, China, April 14, 2026 /PRNewswire/ -- In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell Therapy (XS411) for Primary Parkinson's Disease". ...

2026-04-14 22:00 2357

Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at American Association for Cancer Research Annual Meeting 2026

Data Demonstrate Activity in HER2-Low and ADC-Resistant Tumor Models, Supporting Advancement Toward IND SHANGHAI and SUZHOU, China, April 14, 2026 /PRNewswire/ -- Phrontline Biopharma today announced the presentation of preclinical data for TJ106, a next-generation biparatopic HER2-targeting ant...

2026-04-14 21:08 2207

Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma

SYDNEY, April 14, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Com...

2026-04-14 21:02 1695

Telix Refinances Convertible Bonds

MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) ("Telix") today launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc....

2026-04-14 16:32 2471

Senhwa Biosciences Secures Strategic Backing from Global Investor GEM with Up to NT$500 Million to Accelerate AI-Driven Drug Development

TAIPEI and SAN DIEGO, April 14, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced today the signing of a Memorandum of Understanding (MOU) with GEM YIELD BAHAMAS LIMITED, an affiliate of the global investment firm Global Emerging Mark...

2026-04-14 15:11 2032

Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO

CHENGDU, China, April 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that results from both the ovarian cancer cohort and the cervical cancer cohort of Phase II study SKB264-II-06/MK-2870-002 of the TROP2 ADC sacit...

2026-04-14 08:00 2285

Noah Medical Launches Deep-Dive Research Series on Medical Robotics Value

Why the World's Leading Medical Robotics Companies Put Clinical Value First This article serves as a foundational study for the Noah Medical deep-dive series, aiming to help investors establish a core framework for assessing value in the medical robotics industry. HONG KONG, April 13, 2026 /PRNe...

2026-04-13 17:40 1870

Caliway's Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204's Demonstrated Efficacy and Safety Gain Further Academic Recognition

* Clinical results from Caliway's CBL-0204 Phase 2b study of its fat reduction drug candidate CBL-514 for localized fat reduction have been accepted by theAesthetic Surgery Journal (ASJ), a leading academic journal in aesthetic medicine and plastic surgery. * Following the publication of CBL-...

2026-04-13 16:34 2467

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

BEIJING, April 13, 2026 /PRNewswire/ -- On April 10, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants AbbVie the e...

2026-04-13 14:24 2457

AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer

TAIPEI, April 13, 2026 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotechnology company focused on precision oncology, today announced that two key research abstracts regarding its lead compound, Imofinostat (ABT-301), have been selected for poster presentations at the 2026 American A...

2026-04-13 12:00 2312

Telix and Regeneron Announce Strategic Radiopharma Collaboration

* Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. * Collaboration combines Telix's expertise in radiopharmaceutical development and manufacturing with Regeneron's leading antibody discovery/developme...

2026-04-13 06:57 2140

SINGAPORE STRENGTHENS SARCOMA CARE THROUGH COORDINATED, MULTIDISCIPLINARY APPROACH

NCIS leads multi-institutional effort to develop expert multidisciplinary guidance to improve sarcoma diagnosis, referrals and outcomes SINGAPORE, April 11, 2026 /PRNewswire/ -- Singapore is strengthening its approach to sarcoma care, a rare group of bone and soft tissue cancers that disproporti...

2026-04-11 16:20 2701

Ceva Animal Health appoints Sébastien Huron as Deputy Chief Executive Officer

LIBOURNE, France, April 10, 2026 /PRNewswire/ -- Ceva Animal Health, the world's fifth largest animal health company, majority-owned by its management team, today announces the appointment of Sébastien Huron as Deputy Chief Executive Officer, effective immediately. This move forms part of a broad...

2026-04-10 14:00 3002

ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406

SHANGHAI, April 10, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the first cohort of healthy volunteers has been dosed in a phase I clinical trial of AK0406, a novel long-acting antiviral drug-Fc conjugate (ADFC) drug for influenza infection, follo...

2026-04-10 09:00 3804

Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer

* Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3 investme...

2026-04-10 08:30 3855
12345 ... 339